Production and glycosylation of plant-made pharmaceuticals: the antibodies as a challenge

Summary Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for these molecules. In order to satisfy this growing demand and to increase the...

Full description

Saved in:
Bibliographic Details
Published inPlant biotechnology journal Vol. 2; no. 2; pp. 83 - 100
Main Authors Gomord, Véronique, Sourrouille, Christophe, Fitchette, Anne-Catherine, Bardor, Muriel, Pagny, Sophie, Lerouge, Patrice, Faye, Loïc
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.03.2004
Subjects
antibody
biotechnology
glycosylation
molecular farming
plant-made pharmaceuticals
recombinant protein
transgenic plant
Online AccessGet full text

Cover

More Information
Summary:Summary Antibodies have long been recognized for their diagnostic and therapeutic potential. The rapidly increasing number of monoclonal antibodies approved for immunotherapy has paved the way to an even greater demand for these molecules. In order to satisfy this growing demand and to increase the production capacity, alternative systems based on antibody production in transgenic organisms are being actively explored. In this paper, we focus on transgenic plants as a promising system for the scale‐up and processing of plant‐made pharmaceuticals. In particular, we point out the advantages and limitations induced by glycosylation of plant‐made antibodies for human therapy.
Bibliography:istex:61AFA5468465E36389CE6D05BAB7A9239C5234E1
ArticleID:PBI062
ark:/67375/WNG-9F8HLK7Q-G
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1467-7644
1467-7652
DOI:10.1111/j.1467-7652.2004.00062.x